Welcome to BioSeeker Group!

Global Pipeline Review & Analysis of Hematological Malignancies

Additional Information

Published Date Mar 27, 2007
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 195
PDF Fact Sheet View Fact Sheet for the report Global Pipeline Review & Analysis of Hematological Malignancies in PDF
Format PDF
Publisher BioSeeker Group
Product Line View All Available Cancer Highlights Reports

Availability: In stock

$2,450.00

Quick Overview

In this unique report the hematological cancer pipeline is analyzed and cross referenced by: Investigator,Drug, Sub-indication, Developmental stage, Compound type, Targeted therapy strategy, Target, and Signaling pathway.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Global Pipeline Review & Analysis of Hematological Malignancies.

    To find out more about Global Pipeline Review & Analysis of Hematological Malignancies, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Global Pipeline Review & Analysis of Hematological Malignancies is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Introduction

The markets segments for therapeutics for hematological malignancies are numerous and complicated. The historical general conception that relatively low prevalence diseases, has been insufficient in size to allow companies to quickly regain their investment is clearly out of date. In this perspective enhanced development is expected. Among the emerging therapeutic strategies, passive and active immunotherapies have clearly continued to be leading strategies. Small molecule apoptotic inducers and kinase inhibitors are as well in the forefront.

About this report

In this unique report, Global Pipeline Review & Analysis of Hematological Malignancies, BioSeeker reports on the hematological cancer pipeline by:

  • Investigator – Includes 212 investigators and partners
  • Drug – Includes 237 "active" drugs
  • Sub-indication – Includes 11 sub-indications
  • Developmental stage – Includes 8 developmental stages
  • Compound type – Includes 21 different compounds types
  • Targeted therapy strategy – Includes 5 different targeted therapy strategies
  • Target – Includes 97 different protein targets
  • Signaling pathway – Includes 18 different signaling pathways

All of above "factors" are cross referenced against each other, generating highly valuable insights in 40 figures and 53 tables. Read more below about each "factor" included in this cutting edge analysis.

Investigator

This report includes 212 investigators and partners from all over the world.

Drug

There are today more than 237 therapeutics for the treatment of hematological cancers, from early preclinical to marketed drugs. Each drug is annotated with a brief drug description.

Sub-indication

The hematological cancer drug pipeline is broken down into 11 sub-indications:

  • Cancer, leukemia, acute lymphocytic
  • Cancer, leukemia, acute myelogenous
  • Cancer, leukemia, chronic lymphocytic
  • Cancer, leukemia, chronic myelogenous
  • Cancer, leukemia, general
  • Cancer, leukemia, hairy cell
  • Cancer, lymphoma, B-cell
  • Cancer, lymphoma, general
  • Cancer, lymphoma, Hodgkin`s
  • Cancer, lymphoma, non-Hodgkin`s
  • Cancer, lymphoma, T-cell

Only the highest developmental stage per drug and indication is accounted for.

Developmental Stage

Each sub-indication of a drug is described with its developmental stage:

  • Preclinical
  • Clinical Trial
  • Phase I Clinical Trial
  • Phase II Clinical Trial
  • Phase III Clinical Trial
  • Pre-registration
  • Registered
  • Marketed

Compound Type

BioSeeker has described all 237 drugs in the hematological malignancies pipeline with its corresponding compound type:

  • Biological
  • Biological, bacterial cells
  • Biological, cellular, autologous
  • Biological, cellular, heterologous
  • Biological, nucleic acid
  • Biological, nucleic acid, non-viral vector
  • Biological, nucleic acid, viral vector
  • Biological, peptide
  • Biological, peptide, recombinant
  • Biological, protein
  • Biological, protein, antibody
  • Biological, protein, recombinant
  • Chemical, semisynthetic
  • Chemical, synthetic
  • Chemical, synthetic, isomeric
  • Chemical, synthetic, nucleic acid
  • Chemical, synthetic, peptide
  • Natural product
  • Natural product, animal
  • Natural product, bacterial
  • Natural product, plant

When available, drug compounds are further described with chemical name, CAS number, chemical formula and molecular weight.

Targeted Therapy Strategy

This report categorizes available drugs into 5 major targeted therapy strategies:
1.Angiogenesis
2. Antibody
3. Apoptosis
4. Protein Kinase Inhibitors
5. Vaccines

Target

This analysis includes 97 protein targets, linked to 165 drugs for the treatment of hematological cancers. All protein targets are described by its primary localization, molecular class, molecular function, and biological process:

Primary Localization of Target:

  • Cell surface
  • Centrosome
  • Cytoplasm
  • Cytosol
  • Endoplasmic reticulum
  • Extracellular
  • Integral to membrane
  • Lysosome
  • Mitochondrial membrane
  • Mitochondrion
  • Nucleus
  • Plasma membrane
  • Secretory granule

Molecular Class of Target:

  • Adapter molecule
  • Adhesion molecule
  • Cell cycle control protein
  • Cell surface receptor
  • Chaperone
  • Cysteine protease
  • Cytokine
  • Cytokine receptor
  • Cytoskeletal protein
  • DNA methyltransferase
  • DNA polymerase
  • DNA repair protein
  • Enzyme: Deaminase
  • Enzyme: Decarboxylase
  • Enzyme: Hydrolase
  • Enzyme: Ligase
  • Enzyme: Oxidoreductase
  • Enzyme: Phosphorylase
  • Enzyme: Topoisomerase
  • Enzyme: Transferase
  • G protein coupled receptor
  • Growth factor
  • Integral membrane protein
  • Ligand
  • Lipid phosphatase
  • Membrane bound ligand
  • MHC complex protein
  • Nuclear receptor
  • Receptor tyrosine kinase
  • Serine protease
  • Serine/threonine kinase
  • T cell antigen receptor
  • Transcription factor
  • Transcription regulatory protein
  • Translation regulatory protein
  • Transport/cargo protein
  • Tyrosine kinase
  • Unclassified

Molecular Function of Target:

  • Carboxy-lyase activity
  • Cell adhesion molecule activity
  • Chaperone activity
  • Cysteine-type peptidase activity
  • Cytokine activity
  • Deaminase activity
  • DNA repair protein
  • DNA topoisomerase activity
  • DNA-directed DNA polymerase activity
  • DNA-methyltransferase activity
  • G-protein coupled receptor activity
  • Growth factor activity
  • Hydrolase activity
  • Kinase activity
  • Ligand-dependent nuclear receptor activity
  • Ligase activity
  • Lipid phosphatase activity
  • MHC class I receptor activity
  • Molecular function unknown
  • Oxidoreductase activity
  • Phosphorylase activity
  • Protein binding
  • Protein serine/threonine kinase activity
  • Protein-tyrosine kinase activity
  • Receptor activity
  • Receptor binding
  • Receptor signaling complex scaffold activity
  • Serine-type peptidase activity
  • Structural constituent of cytoskeleton
  • T cell receptor activity
  • Transcription factor activity
  • Transcription regulator activity
  • Transferase activity
  • Translation regulator activity
  • Transmembrane receptor activity
  • Transmembrane receptor protein tyrosine kinase activity
  • Transporter activity
  • Unclassified

Biological Process of Target:

  • Anti-apoptosis
  • Apoptosis
  • Cell communication
  • Cell communication ; Cell surface receptor linked signal transduction
  • Cell communication ; Signal transduction
  • Cell communication ; Signal transduction ; Transport
  • Cell growth and/or maintenance
  • Enzyme linked receptor protein signaling pathway ; Cellular morphogenesis during differentiation
  • Immune response
  • Metabolism
  • Metabolism ; Energy pathways
  • Protein metabolism
  • Protein modification
  • Regulation of cell cycle
  • Regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolism
  • Signal transduction
  • Transport

Signaling Pathway

The 97 available protein targets have been compared with molecular entities in known signaling pathways. This analysis showed the involvement of hematological drugs in at least 18 different signaling pathways:

  • Alpha6 Beta4 Integrin Signaling Pathway
  • Androgen Receptor Signaling Pathway
  • B Cell Receptor Signaling Pathway
  • EGFR1 Signaling Pathway
  • ID Signaling Pathway
  • IL-1 Singaling Pathway
  • IL-2 Signaling Pathway
  • IL-3 Signaling Pathway
  • IL-4 Signaling Pathway
  • IL-5 Signaling Pathway
  • IL-6 Signaling Pathway
  • IL-7 Signaling Pathway
  • Kit Receptor Signaling Pathway
  • Notch Signaling Pathway
  • T Cell Receptor Signaling Pathway
  • TGF-beta Receptor Signaling Pathway
  • TNF-alpha Signaling Pathway
  • Wnt Signaling Pathway

 

1 EXECUTIVE SUMMARY

2 CANCER HIGHLIGHTS

TABLE OF CONTENTS
2.1 LIST OF FIGURES
2.2 LIST OF TABLES

3 PLAYERS IN THE FIELD OF HEMATOLOGICAL MALIGNANCIES

4 THE HEMATOLOGICAL CANCER DRUG PIPELINE
4.1 DRUG PIPELINE BY LEUKEMIA
4.2 DRUG PIPELINE BY LYMPHOMA

5 PROTEIN TARGETS IN HEMATOLOGICAL CANCERS
5.1 PURSUED TARGETS IN LEUKEMIA
5.2 PURSUED TARGETS IN LYMPHOMA

6 COMPOUNDS
6.1 OVERVIEW OF COMPOUNDS
6.2 PRESENTATION OF BIOLOGICAL COMPOUNDS USED IN HEMATOLOGICAL CANCERS
6.3 PRESENTATION OF CHEMICAL COMPOUNDS USED IN HEMATOLOGICAL CANCERS
6.4 PRESENTATION OF NATURAL COMPOUNDS USED IN HEMATOLOGICAL CANCERS
6.5 LEUKEMIA BY COMPOUND TYPES
6.6 LYMPHOMA BY COMPOUND TYPE

7 TARGETED THERAPIES IN HEMATOLOGICAL CANCERS
7.1 TARGETED THERAPIES IN LEUKEMIA
7.2 TARGETED THERPIES IN LYMPHOMA

8 TARGETED THERAPY STRATEGIES VERSUS COMPOUND TYPES IN
HEMATOLOGICAL CANCERS
8.1 TARGETED THERAPY STRATEGIES VERSUS COMPOUND TYPES IN LEUKEMIA
8.2 TARGETED THERAPY STRATEGIES VERSUS COMPOUND TYPES IN LYMPHOMA

9 PURSUED SIGNALING PATHWAYS IN HEMATOLOGICAL CANCERS
9.1 ALPHA6 BETA4 INTEGRIN SIGNALING PATHWAY
9.1.1 DESCRIPTION OF PATHWAY
9.1.2 HEMATOLOGICAL CANCER DRUG CANDIDATES
9.2 ANDROGEN RECEPTOR SIGNALING PATHWAY
9.2.1 DESCRIPTION OF PATHWAY
9.2.2 HEMATOLOGICAL CANCER DRUG CANDIDATES
9.3 B CELL RECEPTOR SIGNALING PATHWAY
9.3.1 DESCRIPTION OF PATHWAY
9.3.2 HEMATOLOGICAL CANCER DRUG CANDIDATES
9.4 EGFR1 SIGNALING PATHWAY
9.4.1 DESCRIPTION OF PATHWAY
9.4.2 HEMATOLOGICAL CANCER DRUG CANDIDATES
9.5 ID SIGNALING PATHWAY
9.5.1 DESCRIPTION OF PATHWAY
9.5.2 HEMATOLOGICAL CANCER DRUG CANDIDATES
9.6 IL-1 SIGNALING PATHWAY
9.6.1 DESCRIPTION OF PATHWAY
9.6.2 HEMATOLOGICAL CANCER DRUG CANDIDATES
9.7 IL-2 SIGNALING PATHWAY
9.7.1 DESCRIPTION OF PATHWAY
9.7.2 HEMATOLOGICAL CANCER DRUG CANDIDATES
9.8 IL-3 SIGNALING PATHWAY
9.8.1 DESCRIPTION OF PATHWAY
9.8.2 HEMATOLOGICAL CANCER DRUG CANDIDATES
9.9 IL-4 SIGNALING PATHWAY
9.9.1 DESCRIPTION OF PATHWAY
9.9.2 HEMATOLOGICAL CANCER DRUG CANDIDATES
9.10 IL-5 SIGNALING PATHWAY
9.10.1 DESCRIPTION OF PATHWAY
9.10.2 HEMATOLOGICAL CANCER DRUG CANDIDATES
9.11 IL-6 SIGNALING PATHWAY
9.11.1 DESCRIPTION OF PATHWAY
9.11.2 HEMATOLOGICAL CANCER DRUG CANDIDATES
9.12 IL-7 SIGNALING PATHWAY
9.12.1 DESCRIPTION OF PATHWAY
9.12.2 HEMATOLOGICAL CANCER DRUG CANDIDATES
9.13 KIT RECEPTOR SIGNALING PATHWAY
9.13.1 DESCRIPTION OF PATHWAY
9.13.2 HEMATOLOGICAL CANCER DRUG CANDIDATES
9.14 NOTCH SIGNALING PATHWAY
9.14.1 DESCRIPTION OF PATHWAY
9.14.2 HEMATOLOGICAL CANCER DRUG CANDIDATES
9.15 T CELL RECEPTOR SIGNALING PATHWAY
9.15.1 DESCRIPTION OF PATHWAY
9.15.2 HEMATOLOGICAL CANCER DRUG CANDIDATES
9.16 TGF-BETA RECEPTOR SIGNALING PATHWAY
9.16.1 DESCRIPTION OF PATHWAY
9.16.2 HEMATOLOGICAL CANCER DRUG CANDIDATES
9.17 TNF-ALPHA SIGNALING PATHWAY
9.17.1 DESCRIPTION OF PATHWAY
9.17.2 HEMATOLOGICAL CANCER DRUG CANDIDATES
9.18 WNT SIGNALING PATHWAY
9.18.1 DESCRIPTION OF PATHWAY
9.18.2 HEMATOLOGICAL CANCER DRUG CANDIDATES

10 BRIEF DRUG DESCRIPTION

11 DISCLAIMER
11.1 LIABILITY
11.2 COMPLETENESS

2.1 List of Figures
Figure 1: The Hematological Cancer Developmental Pipeline
Figure 2: The Leukemia Developmental Pipeline
Figure 3: The Lymphoma Developmental Pipeline
Figure 4: Leukemia Drug Candidates by Developmental Stage, Sub-indication Vrs Primary Target Localization
Figure 5: Leukemia Drug Candidates by Developmental Stage, Sub-indication Vrs Biological Process of Target
Figure 6: Leukemia Drug Candidates by Developmental Stage and Sub-indication Vrs Molecular Class of Target
Figure 7: Lymphoma Drug Candidates by Developmental Stage, Sub-indication Vrs Primary Target Localization
Figure 8: Lymphoma Drug Candidates by Developmental Stage, Sub-indication Vrs Biological Process of Target
Figure 9: Lymphoma Drug Candidates by Developmental Stage, Sub-indication Vrs Molecular Class of Target
Figure 10: Distribution of Compound Types in the Hematological Malignancies Pipeline
Figure 11: Leukemia Drug Candidates Presented by Developmental Stage and Sub-Indication Vrs Compound Typ
Figure 12: Lymphoma Drug Candidates Presented by Developmental Stage and Sub-Indication Vrs Compound Type
Figure 13: Leukemia Drug Candidates by Developmental Stage and Sub-indication Vrs Targeted Therapy Type
Figure 14: Lymphoma Drug Candidates by Developmental Stage and Sub-indication Vrs Targeted Therapy Type
Figure 15: Angiogenesis – Developmental Stages of Sub indications of Leukemia Versus Compound Type
Figure 16: Apoptosis – Developmental Stages of Sub indications of Leukemia Versus Compound Type
Figure 17: Protein Kinase Inhibitors – Developmental Stages of Sub indications of Leukemia Versus Compound Type
Figure 18: Vaccines – Developmental Stages of Sub indications of Leukemia Versus Compound Type
Figure 19: Angiogenesis – Developmental Stages of Sub indications of Lymphoma Versus Compound Type
Figure 20: Apoptosis – Developmental Stages of Sub indications of Lymphoma Versus Compound Type
Figure 21: Protein Kinase Inhibitor – Developmental Stages of Sub indications of Lymphoma Versus Compound Type
Figure 22: Vaccines – Developmental Stages of Sub indications of Lymphoma Versus Compound Type
Figure 23: Drug Candidates Involving the Alpha6 Beta4 Integrin Signaling Pathway for the Treatment of Hematological Cancers
Figure 24: Drug Candidates Involving the Androgen Receptor Signaling Pathway for the Treatment of Hematological Cancers
Figure 25: Drug Candidates Involving the B Cell Receptor Signaling Pathway for the Treatment of Hematological Cancers
Figure 26: Drug Candidates Involving the EGFR1 Signaling Pathway for the Treatment of Hematological Cancers
Figure 27: Drug Candidates Involving the ID Signaling Pathway for the Treatment of Hematological Cancers
Figure 28: Drug Candidates Involving the IL-1 Signaling Pathway for the Treatment of Hematological Cancers
Figure 29: Drug Candidates Involving the IL-2 Signaling Pathway for the Treatment of Hematological Cancers
Figure 30: Drug Candidates Involving the IL-3 Signaling Pathway for the Treatment of Hematological Cancers
Figure 31: Drug Candidates Involving the IL-4 Signaling Pathway for the Treatment of Hematological Cancer
Figure 32: Drug Candidates Involving the IL-5 Signaling Pathway for the Treatment of Hematological Cancers
Figure 33: Drug Candidates Involving the IL-6 Signaling Pathway for the Treatment of Hematological Cancers
Figure 34 Drug Candidates Involving the IL-7 Signaling Pathway for the Treatment of Hematological Cancers
Figure 35: Drug Candidates Involving the Kit Receptor Signaling Pathway for the Treatment of Hematological Cancers
Figure 36: Drug Candidates Involving the Notch Signaling Pathway for the Treatment of Hematological Cancers
Figure 37: Drug Candidates Involving the T Cell Receptor Signaling Pathway for the Treatment of Hematological Cancers
Figure 38: Drug Candidates Involving the TGF-beta Receptor Signaling Pathway for the Treatment of Hematological Cancers
Figure 39: Drug Candidates Involving the TNF-alpha Signaling Pathway for the Treatment of Hematological Cancers
Figure 40: Drug Candidates Involving the Wnt Signaling Pathway for the Treatment of Hematological Cancers

2.2 List of Tables
Table 1: List of Active Players in the Field of Hematological Malignancies
Table 2: The Leukemia Developmental Pipeline
Table 3: The Lymphoma Developmental Pipeline
Table 4: List of Pursued Protein Targets in Hematological Cancers
Table 5: Hematological Cancer Targets by Investigator and Drug
Table 6: Pursued Targets by Sub-indications of Leukemia
Table 7: Pursued Targets by Sub-indications of Lymphoma
Table 8: Drug Candidates with Its Corresponding Compound Types Listed by Investigator
Table 9: List of Biological Compounds
Table 10: List of Chemical Compounds
Table 11: List of Natural Compounds
Table 12: Developmental Stage and Sub Indication by Compounds Type in Leukemia
Table 13: Developmental Stage and Sub indication bt Compound Types in Lymphoma
Table 14: List of Targeted Therapies in Leukemia100
Table 15: List of Targeted Therapies in Lymphoma
Table 16: Targeted Therapy Strategies Versus Compound Type in Leukemia
Table 17: Targeted Therapy Strategies Versus Compound Types in Lymphoma
Table 18: Targets Linking Drugs to the Alpha6 Beta4 Integrin Signaling Pathway
Table 19: Drugs, Listed by Sub Indication and Developmental Stage, Targeting the Alpha6 Beta4 Integrin Signaling Pathway
Table 20: Targets Linking Drugs to the Androgen Receptor Signaling Pathway
Table 21: Drugs, Listed by Sub Indication and Developmental Stage, Targeting the Androgen Receptor Signaling Pathway
Table 22: Targets Linking Drugs to the B Cell Receptor Signaling Pathway
Table 23: Drugs, Listed by Sub Indication and Developmental Stage, Targeting the B Cell Receptor Signaling Pathway
Table 24: Targets Linking Drugs to the EGFR1 Signaling Pathway
Table 25: Drugs, Listed by Sub Indication and Developmental Stage, Targeting the EGFR1 Signaling Pathway
Table 26: Targets Linking Drugs to the ID Signaling Pathway
Table 27: Drugs, Listed by Sub Indication and Developmental Stage, Targeting the ID Signaling Pathway
Table 28: Targets Linking Drugs to the IL-1 Signaling Pathway
Table 29: Drugs, Listed by Sub Indication and Developmental Stage, Targeting the IL-1 Signaling Pathway
Table 30: Targets Linking Drugs to the IL-2 Signaling Pathway
Table 31: Drugs, Listed by Sub Indication and Developmental Stage, Targeting the IL-2 Signaling Pathway
Table 32: Targets Linking Drugs to the IL-3 Signaling Pathway
Table 33: Drugs, Listed by Sub Indication and Developmental Stage, Targeting the IL-3 Signaling Pathway
Table 34: Targets Linking Drugs to the IL-4 Signaling Pathway
Table 35: Drugs, Listed by Sub Indication and Developmental Stage, Targeting the IL-4 Signaling Pathway
Table 36: Targets Linking Drugs to the IL-5 Signaling Pathway
Table 37: Drugs, Listed by Sub Indication and Developmental Stage, Targeting the IL-5 Signaling Pathway
Table 38: Targets Linking Drugs to the IL-6 Signaling Pathway
Table 39: Drugs, Listed by Sub Indication and Developmental Stage, Targeting the IL-6 Signaling Pathway
Table 40: Targets Linking Drugs to the IL-7 Signaling Pathway
Table 41: Drugs, Listed by Sub Indication and Developmental Stage, Targeting the IL-7 Signaling Pathway
Table 42: Targets Linking Drugs to the Kit Receptor Signaling Pathway
Table 43: Drugs, Listed by Sub Indication and Developmental Stage, Targeting the Kit Receptor Signaling Pathway
Table 44: Targets Linking Drugs to theNotch Signaling Pathway
Table 45: Drugs, Listed by Sub Indication and Developmental Stage, Targeting the Notch Signaling Pathway
Table 46: Targets Linking Drugs to the T Cell Receptor Signaling Pathway
Table 47: Drugs, Listed by Sub Indication and Developmental Stage, Targeting the T Cell Receptor Signaling Pathway
Table 48: Targets Linking Drugs to the TGF-beta Signaling Pathway
Table 49: Drugs, Listed by Sub Indication and Developmental Stage, Targeting the TGF-beta Receptor Signaling Pathway
Table 50: Targets Linking Drugs to the TNF-alpha Signaling Pathway
Table 51: Drugs, Listed by Sub Indication and Developmental Stage, Targeting the TNF-alpha Signaling Pathway
Table 52: Targets Linking Drugs to the Wnt Signaling Pathway
Table 53: Drugs, Listed by Sub Indication and Developmental Stage, Targeting the Wnt Signaling Pathway

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Global Pipeline Review & Analysis of Hematological Malignancies.
    To find out more about Global Pipeline Review & Analysis of Hematological Malignancies, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Global Pipeline Review & Analysis of Hematological Malignancies is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Cancer Highlights' category:


Portfolio Analytics and Planning in the Breast Cancer Pipeline - Change is Around the Corner in a Highly Competitive Market Place
This report comprises defined and up to date development strategies for 405 breast cancer drugs within the portfolio of 220 investigators, from Ceased to Marketed. The report extensively analyses 207 identified targets of breast cancer drugs, organized into 193 drug target strategies, and assesses them in breast cancer. Significantly new breast cancer therapies will soon come to challenge old established drugs on the market. Learn More


Targeted Therapeutics in Non-Small Cell Lung Cancer
With this report you will be able to track down and foresee activities associated with the development of new treatments for NSCLC. Learn More

Other selected research from the 'Oncology' category:


Triple Analysis: Pancreatic Cancer, Antibodies and Peptides
This triple analysis focuses on cancer drug development strategies in Pancreatic Cancer and by the two compound strategies of Antibodies and Peptides. Learn More


Epigenetic Therapy in Oncology Drug Pipeline Update
BioSeeker Group have identified 101 companies plus partners who are today developing 129 epigenetic therapy drugs in 477 developmental projects in cancer across 57 different targets. In addition, there is 1 suspended drug and another 36 drugs where development has been ceased. Learn More